Last reviewed · How we verify
NCT05376904
A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.
Phase 2 trial testing HR18034 in Postsurgical Pain Management in 86 participants. Completed in 5 October 2022.
5 October 2022
Quick facts
| Lead sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 13 June 2022 |
| Primary completion | 5 October 2022 |
| Estimated completion | 5 October 2022 |
| Sites | 18 locations across China |
Drugs / interventions tested
- HR18034 — full drug profile →
- HR18034 — full drug profile →
- HR18034 — full drug profile →
- ropivacaine HCl. — full drug profile →
Conditions studied
- Postsurgical Pain Management — all drugs for Postsurgical Pain Management →
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Postsurgical Pain Management. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy. To explore the reasonable dosage of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05376904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HR18034
Trials testing the same drug.
- NCT06509958 — Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA · Phase 2 · terminated
- NCT05769855 — A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy · Phase 3 · completed
- NCT05744674 — Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management · Phase 2 · unknown
- NCT04551924 — A Trial of HR18034 in Inguinal Hernia Repair · Phase 1 · unknown
Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
- NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
- NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
- NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05376904 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
- Last refreshed: 20 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05376904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing